Docteur GUILLAUME DECARRIERE

Bibliographie

• Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study

  2024

  ArticleRMD Open

• Most Appropriate Conventional Disease‐Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta‐Analysis

  2021

  ArticleArthritis Care & Research = Arthritis Care and Research

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CH PERPIGNAN

  20 Avenue DU LANGUEDOC, 66046 Perpignan

  ☎ 0468616633Hospitalier🏥 Centre CH ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (1)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Riches rencontres lors de la Journée mondiale de la Sclérodermie - lepetitjournal.net

  📰 lepetitjournal.net · 01/10/2024

  <a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPNUVsdG4zLURZYWdBTXhDakkzVmNJa0NOWU5Ua1I1MTRHZzB3amNEb0ZMUTI5ZFBxeE9zYmpIbHhvV3U5Q0RTY24xeF8weFh2bGxWNG9MZGZJdGhRZ0R5QmhVeWJ0Mm5aS1hWN1E2R1RTSEJQTnRoUnZTZGtwTHZXUWpTUzQxbklTbDJ2anc1bEszWnRVTy04VVNCMk9KYVRSb1dnZV9Bc3JTUTFHcFVmYzk4ZG9jWG13Un

Top publications · les plus citées

• 1

  Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study

  RMD open · 2024

  📚 2 citations🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Rational Studies are needed to determine if multimorbidity screening and management reduce the rate of multimorbidity accumulation in patients with chronic inflammatory rheumatic diseases (IRD). Objectives This study evaluates the impact of systematic screening programme on patient care and hospitalisation rates. Methods Patients with IRD who participated in the screening programme (exposed patients) were identified within the French national health database and matched with controls. Two sets of analysis were performed: one with multivariate analysis and a second using a propensity score matching to ensure comparability between exposed patients and controls. The primary endpoint (PE) was a composite score assessing the dispensation of multimorbidity-preventing drugs, including vaccines, lipid-lowering agents, antiosteoporotic medications and antiplatelet drugs, during the year following the index date. Results The first analysis included 286 exposed patients and 858 controls, demonstrating a higher rate of meeting the PE in exposed patients (adjusted OR=1.6 (1.2–2.2), p&lt;0.01). Propensity score matching resulted in 281 exposed patients and 281 controls. Exposed patients exhibited a significantly higher rate of meeting the PE compared with controls (54.8% vs 44.5%; OR=1.5; p=0.015), with increased utilisation of vaccines, cholesterol-lowering drugs and antiosteoporotic medications. Furthermore, emergency admission and hospitalisations for fracture, cardiovascular events or infection were significantly less frequent in the exposed group (7.1% vs 15.3%; OR=0.42, p&lt;0.01), with a reduction in severe infections (0.7% vs 3.9%; p=0.03). Conclusion Systematic multimorbidity screening in patients with IRD boosted preventive medication use and reduced hospital admissions, justifying time and resource allocation for screening.

• 2

  Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis

  Arthritis care & research · 2021

  📚 2 citations

  Lire l'abstract Crossref ↓

  ObjectiveIn rheumatoid arthritis, the association between advanced therapies (including biologic disease‐modifying antirheumatic drugs [DMARDs] and targeted synthetic DMARDs) and methotrexate (MTX) is recommended by international societies. When MTX cannot be used, other conventional synthetic DMARDs (csDMARDs) may be proposed. We aimed to compare the safety and efficacy of MTX and non‐MTX csDMARDs in combination with advanced therapies.MethodsWe systematically searched the literature for studies comparing the effectiveness, retention rate, and safety of MTX versus non‐MTX csDMARDs (leflunomide or others) in combination with tumor necrosis factor inhibitors (TNFi), abatacept, rituximab, tocilizumab, and JAK inhibitors. Meta‐analysis was performed with RevMan, using an inverse variance approach with fixed or random‐effects models. Risk ratios (RRs) and 95% confidence intervals (95% CIs) were estimated.ResultsThe literature search revealed 3,842 articles; 41 studies were included for the systematic literature review and 21 for the meta‐analysis: 13 with TNFi, 3 with abatacept, and 5 with rituximab. For TNFi, the European Alliance of Associations for Rheumatology (EULAR) response at 6 months was lower for patients receiving non‐MTX csDMARDs than for those using MTX (RR 0.93 [95% CI 0.87, 1.0], P = 0.04; n = 3,843; I2 = 28%), with a lower retention rate at 12 months. For abatacept, effectiveness and safety were similar between the 2 groups. For rituximab, a good EULAR response was higher with leflunomide than MTX (RR 1.38 [95% CI 1.13, 1.68], P = 0.001; n = 2,078; I2 = 0%), with similar adverse event rates. Meta‐analysis for tocilizumab or JAK inhibitors could not be performed.ConclusionThe different csDMARDs seem safe and efficient to combine with advanced therapies in RA patients. Although MTX seems slightly superior to other csDMARDs in combination with TNFi, leflunomide might be superior to MTX in combination with rituximab.

Publications scientifiques (2) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche